Related Experiment Video
Updated: Apr 4, 2026
Laser Capture Microdissection of Mouse Embryonic Cartilage and Bone for Gene Expression Analysis
Published on: December 18, 2019
Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2
Mattia Capulli1, Antonio Maurizi1, Luca Ventura2
1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Abstract:
In about 70% of patients affected by autosomal dominant osteopetrosis type 2 (ADO2), osteoclast activity is reduced by heterozygous mutations of the CLCN7 gene, encoding the ClC-7 chloride/hydrogen antiporter. CLCN7(G215R)-, CLCN7(R767W)-, and CLCN7(R286W)-specific siRNAs silenced transfected mutant mRNA/EGFP in HEK293 cells, in RAW264.7 cells and in human osteoclasts, with no change of CLCN7(WT) mRNA and no effect of scrambled siRNA on the mutant transcripts. Osteoclasts from Clcn7(G213R) ADO2 mice showed reduced bone resorption, a condition rescued by Clcn7(G213R)-specific siRNA. Treatment of ADO2 mice with Clcn7(G213R)-specific siRNA induced increase of bone resorption variables and decrease of trabecular bone mass, leading to an overall improvement of the osteopetrotic bone phenotype. Treatment did not induce overt adverse effects and was effective also with siRNAs specific for other mutants. These results demonstrate that a siRNA-based experimental treatment of ADO2 is feasible, and underscore a translational impact for future strategy to cure this therapeutically neglected form of osteopetrosis.
Insights
This study shows that siRNA targeting mutant CLCN7 gene effectively reduces osteoclast dysfunction in autosomal dominant osteopetrosis type 2 (ADO2). This gene therapy approach improved bone resorption in mouse models, offering a potential treatment for ADO2.
Area of Science:
- Genetics
- Molecular Biology
- Bone Biology
Background:
- Autosomal dominant osteopetrosis type 2 (ADO2) is characterized by reduced osteoclast activity due to mutations in the CLCN7 gene.
- The CLCN7 gene encodes the ClC-7 chloride/hydrogen antiporter, crucial for osteoclast function.
Purpose of the Study:
- To investigate the therapeutic potential of siRNA-based gene silencing for ADO2.
- To assess the efficacy of CLCN7-specific siRNAs in correcting osteoclast dysfunction and improving the osteopetrotic phenotype.
Main Methods:
- Utilized CLCN7-specific siRNAs to silence mutant mRNA in cell lines (HEK293, RAW264.7) and human osteoclasts.
- Administered CLCN7(G213R)-specific siRNA to ADO2 mouse models to evaluate effects on bone resorption and bone mass.
- Assessed safety and efficacy across different CLCN7 mutant types.
Main Results:
- CLCN7-specific siRNAs effectively silenced mutant CLCN7 mRNA without affecting wild-type mRNA.
- Osteoclasts from ADO2 mice exhibited reduced bone resorption, which was rescued by specific siRNA treatment.
- Treatment of ADO2 mice with siRNA increased bone resorption and decreased trabecular bone mass, improving the osteopetrotic phenotype without adverse effects.
Conclusions:
- siRNA-based gene silencing is a feasible experimental treatment for ADO2.
- This approach demonstrates translational potential for developing future therapies for this neglected bone disorder.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...